



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

March 10, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – March 8, 2021

TOTAL Cases Reported Since 1/22/20

28,937,762

NEW Cases Reported to CDC on 3/8/21

41,237

Change in 7-Day Case Average

-14.8%


Current 7-Day Case Average (3/2/21 - 3/8/21)

55,773

Prior 7-Day Case Average (2/23/21 - 3/1/21)

65,461

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
Current	314,172 (1/8/21)	249,360 (1/11/21)
2nd Peak	75,192 (7/17/20)	67,278 (7/23/20)
1st Peak	42,597 (4/6/20)	31,933 (4/12/20)



*7-day averages exclude historical cases reported retroactively by states



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – March 7, 2021

Patients Currently Hospitalized with COVID on 3/7/21

35,205

New Admissions on 3/7/21

4,155

Peak in New Admissions (1/5/21)

18,007

Change in 7-Day Average of New Admissions


-14.9%

Current 7-Day Average of New Admissions (3/1/21 - 3/7/21)

4,946

Prior 7-Day Average of New Admissions (2/22/21 - 2/28/21)

5,812



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – March 8, 2021

TOTAL Deaths Reported Since 1/22/2020

524,695

NEW Deaths Reported to CDC on 3/8/21

845

Change in 7-Day Death Average

-12.5%

Current 7-Day Death Average (3/2/21 - 3/8/21)


1,646

Prior 7-Day Death Average (2/23/21 - 3/1/21)

1,881


Forecasted Total Deaths by 3/27/21

540,000-564,000






WEAR A MASK



STAY 6 FEET APART



AVOID CROWDS



AVOID TRAVEL

SARS-CoV-2 Vaccine Distribution Strategy Aligned to CDC Phases

Total adults - 267 million

Phase 1a (~24M)

- Health care personnel
- Long-term care facility residents

Phase 1b (~49M)

- Frontline essential workers
- Persons aged 75 years and older

Phase 1c (~129M)

- Persons aged 65-74 years
- Persons aged 16-64 years with high-risk conditions
- Essential workers not recommended in Phase 1b

Phase 2 (~65M)

- All people aged 16 years or older not in Phase 1, who are recommended for vaccination



Selected Special Populations for SARS-CoV-2 Vaccination

■ Pregnant individuals

– ~3.7 million births in US (2019)¹

■ Adolescents and children

– ~73 million individuals aged 0-18 years in the US (2019)²

■ Immunocompromised individuals

– i.e. individuals with immunosuppressive medical conditions (primary immunodeficiencies, HIV, etc.) or receiving immunosuppressive treatment/chemotherapy

– Estimated around 3% of US adults (~7-8 million individuals)³

¹CDC, NCHS, 2020

²Census.gov

³Harpaz, *JAMA*, 2016



SARS-CoV-2 Vaccination for Special Populations: Selected Questions

- **What is the safety and immunogenicity profile of SARS-CoV-2 vaccines in certain special populations?**
- **What is the duration of the immune response to vaccination in certain special populations?**
- **What is the efficacy of SARS-CoV-2 vaccination on reducing disease and transmission in certain special populations?**



SARS-CoV-2 Vaccination: Pregnant Individuals

- **The American College of Obstetricians and Gynecologists (ACOG) recommends that SARS-CoV-2 vaccines should not be withheld from pregnant individuals**
 - Pregnant individuals may choose to receive a COVID-19 vaccine
 - A conversation with their clinicians may help them decide
- **CDC has established V-safe pregnancy registry to follow outcomes among vaccinated pregnant individuals**
- **Pfizer/BioNTech launched randomized, placebo-controlled study to evaluate safety/immunogenicity in pregnant individuals**



SARS-CoV-2 Vaccination: Adolescents and Children

■ Age ranges for currently authorized SARS-CoV-2 vaccines

- Moderna: EUA persons aged 18 years and older
- Pfizer/BioNTech: EUA persons aged 16 years and older
- Johnson & Johnson: EUA persons aged 18 years and older

■ Vaccine safety and immunogenicity studies in adolescents and children ongoing and planned

- Pfizer/BioNTech study in persons aged 12-15 years: fully enrolled
- Moderna TeenCOVE study in persons aged 12-17 years: fully enrolled
- Trials in younger children will follow (i.e. Moderna KidCOVE)
- J & J studies planned



SARS-CoV-2 Vaccination: Special Populations- Other Considerations

■ People with HIV

- People with stable HIV infection included in trials, though data are limited**
- HHS HIV/AIDS Guidelines recommend people with HIV should receive SARS-CoV-2 vaccines (regardless of CD4 or viral load) because the potential benefits outweigh potential risks**

■ Highly allergic individuals

- Studies planned**





THE WHITE HOUSE
WASHINGTON

WH.GOV